Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.

ABSTRACT:

Purpose

Currently, there are no accurate markers for predicting potentially lethal prostate cancer (PC) before biopsy. This study aimed to develop urine tests to predict clinically significant PC (sPC) in men at risk.

Methods

Urine samples from 928 men, namely, 660 PC patients and 268 benign subjects, were analyzed by gas chromatography/quadrupole time-of-flight mass spectrophotometry (GC/Q-TOF MS) metabolomic profiling to construct four predictive models. Model I discriminated between PC and benign cases. Models II, III, and GS, respectively, predicted sPC in those classified as having favorable intermediate risk or higher, unfavorable intermediate risk or higher (according to the National Comprehensive Cancer Network risk groupings), and a Gleason sum (GS) of ≥ 7. Multivar

SUBMITTER: Huang HP 

PROVIDER: S-EPMC10566053 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature